A detailed history of Geode Capital Management, LLC transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,133,535 shares of TNGX stock, worth $9.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,133,535
Previous 1,097,102 3.32%
Holding current value
$9.7 Million
Previous $10.9 Million 17.13%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$7.51 - $12.88 $273,611 - $469,257
36,433 Added 3.32%
1,133,535 $9 Million
Q4 2023

Feb 13, 2024

BUY
$6.52 - $12.01 $404,944 - $745,917
62,108 Added 6.0%
1,097,102 $10.9 Million
Q3 2023

Nov 13, 2023

BUY
$2.93 - $11.26 $281,740 - $1.08 Million
96,157 Added 10.24%
1,034,994 $11.7 Million
Q2 2023

Aug 11, 2023

BUY
$2.67 - $4.7 $138,749 - $244,240
51,966 Added 5.86%
938,837 $3.12 Million
Q1 2023

May 15, 2023

BUY
$3.76 - $8.06 $129,731 - $278,094
34,503 Added 4.05%
886,871 $3.5 Million
Q4 2022

Feb 13, 2023

BUY
$3.41 - $8.29 $42,983 - $104,495
12,605 Added 1.5%
852,368 $6.18 Million
Q3 2022

Nov 14, 2022

SELL
$3.25 - $5.46 $489,895 - $823,024
-150,737 Reduced 15.22%
839,763 $3.04 Million
Q2 2022

Aug 12, 2022

BUY
$3.86 - $8.01 $1.53 Million - $3.18 Million
397,158 Added 66.94%
990,500 $4.49 Million
Q1 2022

May 13, 2022

BUY
$7.01 - $10.94 $43,216 - $67,445
6,165 Added 1.05%
593,342 $4.5 Million
Q4 2021

Feb 11, 2022

BUY
$9.55 - $14.29 $1.51 Million - $2.27 Million
158,542 Added 36.99%
587,177 $6.42 Million
Q3 2021

Nov 12, 2021

BUY
$9.56 - $17.3 $4.1 Million - $7.42 Million
428,635 New
428,635 $5.54 Million

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $754M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.